广西师范大学学报（自然科学版） ›› 2015, Vol. 33 ›› Issue (3): 138-143.doi: 10.16088/j.issn.1001-6600.2015.03.021

• • 上一篇    下一篇

HIV感染者HAART中LEP、HCY的变化及临床意义

李海莉1, 孔衍琳1, 张帅1, 胡婷婷1, 蒋骞1, 李赫伟1, 蒋就喜1, 李林2   

  1. 1.桂林医学院附属医院感染性疾病科,广西桂林541001;
    2.军事医学科学院微生物流行病研究所,北京100071
  • 收稿日期:2015-03-17 出版日期:2015-05-10 发布日期:2018-09-20
  • 通讯作者: 蒋就喜(1955—),男,广西桂林人,桂林医学院教授,硕导。E-mail: gljiangjx@sohu.com
  • 基金资助:
    国家自然科学基金资助项目(81273137);国家传染病重大专项基金资助项目(2012ZX10001-002); 广西本级技术研究与开发基金资助项目(桂财教〔2012〕98号);桂林市科学研究与技术开发基金资助项目(20130120-18)

Clinical Significance of Changes of LEP and HCY Levels in Serum of HIV-infected Patients Receiving Highly Active Antiretroviral Therapy

LI Hai-li1, KONG Yan-lin1, ZHANG Shuai1, HU Ting-ting1, JIANG Qian1, LI He-wei1, JIANG Jiu-xi1, LI Lin2   

  1. 1. Infectious Diseases Department, Affiliated Hospital of Guilin Medical University, Guilin Guangxi 541004, China;
    2. Institute of Microbiology, Epidemiology of Military Medical Sciences,Beijing 100071, China
  • Received:2015-03-17 Online:2015-05-10 Published:2018-09-20

PDF (PC)

248

摘要： 通过检测HIV感染者在高效抗逆转录病毒治疗(highly active anti-retroviral therapy,HAART) 过程中心血管疾病(cardiovascular disease,CVD)的标志物同型半胱氨酸(homocysteine,HCY)和瘦素(leptin,LEP)的含量,判断其在HIV感染人群中对CVD的预防作用。采用酶联免疫吸附实验(ELISA)检测桂林市第三人民医院62例HIV感染者和30名健康对照组血清中LEP和 HCY水平,结果显示,HIV感染治疗组血清HCY的水平明显高于未治疗组与正常对照组,差异具有统计学意义(P<0.01),血清LEP在3组中无明显变化(P>0.05),血清HCY与CD4+T淋巴细胞计数及TG呈正相关作用(P<0.01)。可见,在HIV感染者HAART过程中,动态地检测病人血清HCY水平有助于HIV感染者并发CVD的早期预防,为HIV感染人群并发CVD提供早期预防依据。

关键词: 艾滋病毒感染, 高效抗逆转录病毒治疗, 心血管疾病, 同型半胱氨酸, 瘦素

Abstract: The content of Leptin (LEP) and homocysteine (HCY) of cardiovascular diseases (CVD) markers in HIV infected patients was detected in Highly active antiretroviral therapy (HAART) process and the effect on prevention of CVD in HIV infected patients was determined to provide a basis for early prevention in HIV infection complicated with CVD. Methods: Serum samples obtained from 30 healthy subjects and 62 HIV infected patients(28 treatment nalve and 34 treatment experienced patients) were analyzed by enzyme-linked immunosorbent assay (ELISA) to determine the HCY and LEP contents.The Results show that the level of serum HCY in HIV infected treatment group was obviously higher than that of untreated group and normal control group (P<0.01).There was no marked difference of the LEP level between the three controls(P>0.05). Serum HCY and CD4+T lymphocyte count, treatment time and TG were positively correlated (P<0.01). Dynamically detecting the level of HCY and LEP may be beneficial to the early prevention of HIV infection complicated with CVD.

Key words: HIV, HAART, cardiovascular disease, homocysteine, leptin

中图分类号: 

  • R512.91
[1] FORD E S, GREENWALD J H, RICHTERMAN A G, et al. Traditional risk factors and D-dimer predict incident cardiovascular disease events in chronic HIV infection[J]. AIDS, 2010, 24(10): 1509-1517.
[2] CURRIER J S, LUNDGREN J D, CARR A, et al. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy[J]. Circulation, 2008, 118(2): e29-35.
[3] TRIANT V A, LEE H, HADIGAN C, et al. Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease[J]. J Clin Endocrinol Metab, 2007, 92(7): 2506-2512.
[4] ANUURAD E, SEMRAD A, BERGLUND L. Human immunodeficiency virus and highly active antiretroviral therapy-associated metabolic disorders and risk factors for cardiovascular disease[J]. Metab Syndr Relat Disord, 2009, 7(5): 401-410.
[5] LIEB W, SULLIVAN L M, HARRIS T B, et al. Plasma leptin levels and incidence of heart failure, cardiovascular disease, and total mortality in elderly individuals[J]. Diabetes Care, 2009, 32(4): 612-616.
[6] REEDER S J, HOFFMANN R L, MAGDIC K S, et al. Homocysteine: the latest risk factor for heart disease[J]. Dimens Crit Care Nurs, 2000, 19(1): 22-28.
[7] SACKOFF J E, HANNA D B, PFEIFFER M R, et al. Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City[J]. Ann Intern Med, 2006, 145(6): 397-406.
[8] AHIMA R S, LAZAR M A. Adipokines and the peripheral and neural control of energy balance[J]. Mol Endocrinol, 2008, 22(5): 1023-1031.
[9] DE ROSA V, PROCACCINI C, CALI G, et al. A key role of leptin in the control of regulatory T cell proliferation[J]. Immunity, 2007, 26(2): 241-255.
[10] STEINER A A, ROMANOVSKY A A. Leptin: at the crossroads of energy balance and systemic inflammation[J]. Prog Lipid Res, 2007, 46(2): 89-107.
[11] SANCHEZ-POZO C, RODRIGUEZ-BANO J, DOMINGUEZ-CASTELLANO A, et al. Leptin stimulates the oxidative burst in control monocytes but attenuates the oxidative burst in monocytes from HIV-infected patients[J]. Clin Exp Immunol, 2003, 134(3): 464-469.
[12] PASTERNAK R C, GRUNDY S M, LEVY D, et al. 27th Bethesda Conference: matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 3. Spectrum of risk factors for coronary heart disease[J]. J Am Coll Cardiol, 1996, 27(5): 978-990.
[13] GUARALDI G, VENTURA P, GARLASSI E, et al. Hyperhomocysteinaemia in HIV-infected patients: determinants of variability and correlations with predictors of cardiovascular disease[J]. HIV Med, 2009, 10(1): 28-34.
[14] UCCELLI M C, TORTI C, LAPADULA G, et al. Influence of folate serum concentration on plasma homocysteine levels in HIV-positive patients exposed to protease inhibitors undergoing HAART[J]. Ann Nutr Metab, 2006, 50(3): 247-252.
[15] CORIA-RAMIREZ E, CISNEROS L N, TREVINO-PEREZ S, et al. Effect of highly active antiretroviral therapy on homocysteine plasma concentrations in HIV-1-infected patients[J]. J Acquir Immune Defic Syndr, 2010, 54(5): 477-481.
[16] LIOTTA A, MAGGIO M C, DI C P, et al. Serum leptin and interleukin-6 levels in pediatric patients with HIV[J]. J Pediatr Endocrinol Metab, 2003, 16(2): 179-183.
[17] CARR A, SAMARAS K, THORISDOTTIR A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study[J]. Lancet, 1999, 353(9170): 2093-2099.
[18] SHEVITZ A, WANKE C A, FALUTZ J, et al. Clinical perspectives on HIV-associated lipodystrophy syndrome: an update[J]. AIDS, 2001, 15(15): 1917-1930.
[19] AL-FADHLI M, SARAYA M, QASEM J, et al. Relationship between leptin levels and suppressed CD4 counts in HIV patients[J]. Med Princ Pract, 2013, 22(1): 54-58.
[20] MATARESE G, CASTELLI-GATTINARA G, CANCRINI C, et al. Serum leptin and CD4+T lymphocytes in HIV+ children during highly active antiretroviral therapy[J]. Clin Endocrinol (Oxf), 2002, 57(5): 643-646.
[21] NETO M G, ZWIRTES R, BRITES C. A literature review on cardiovascular risk in human immunodeficiency virus-infected patients: implications for clinical management[J]. Braz J Infect Dis, 2013, 17(6): 691-700.
[22] FRIIS-MOLLER N, WEBER R, REISS P, et al. Cardiovascular disease risk factors in HIV patients-association with antiretroviral therapy: results from the DAD study[J]. AIDS, 2003, 17(8): 1179-1193.
[23] STANLEY T L, GRINSPOON S K. Body composition and metabolic changes in HIV-infected patients[J]. J Infect Dis,2012,205 (S3): S383-390.
[24] UMARANI V, MUVVALA S, RAMESH A, et al. Rutin potentially attenuates fluoride induced oxidative stress mediated cardiotoxicity, blood toxicity and dyslipidemia in rats[J]. Toxicol Mech Methods, 2015, 25(2): 143-149.
[1] 孔衍琳, 张帅, 王雪雯, 李赫伟, 胡婷婷, 蒋骞, 蒋就喜, 潘定权, 张振开, 李林, 孙常荣, 李敬云, 梁浩, 梁冰玉. 广西三城市HIV-1型流行毒株gag基因亚型分析[J]. 广西师范大学学报（自然科学版）, 2015, 33(1): 127-133.
[2] 黄甲清, 张英, 蒋就喜, 胡婷婷, 李赫伟, 曾思恩, 徐茹, 沈建峰, 谢付静. HIV-1感染者血清IL-18及IL-18BP水平的变化及临床意义[J]. 广西师范大学学报（自然科学版）, 2012, 30(4): 110-114.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 广西师范大学学报（自然科学版）编辑部
地址：广西桂林市三里店育才路15号　邮编：541004
电话：0773-5857325　E-mail: gxsdzkb@mailbox.gxnu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发